Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesper Stentoft

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Ugeskrift for Laeger|January 26, 2011
[The pathogenesis of primary immune thrombocytopenia]Sif Gudbrandsdottir, Henrik Frederiksen, Henrik Sverre Birgens, et al.
Ugeskrift for Laeger|January 26, 2011
[New treatment options for primary immune thrombocytopenia]Sif Gudbrandsdottir, Henrik Frederiksen, Henrik Sverre Birgens, et al.
The Lancet. Haematology|December 22, 2015
Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort studyHenrik Frederiksen, Dóra Körmendiné Farkas, Christian Fynbo Christiansen, et al.
Ugeskrift for Laeger|January 29, 2009
[Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences]Peter Hokland, Hans Beier Ommen, Charlotte Guldborg Nyvold, et al.
Ugeskrift for Laeger|January 29, 2009
[Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation]Peter Hokland, Charlotte Guldborg Nyvold, Jesper Stentoft, et al.
Ejhaem|August 22, 2025
Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria: Real World Data From Denmark and FinlandAnders Rønneholt-Frederiksen, Dennis Lund Hansen, Vuokko Nummi, et al.
Ugeskrift for Laeger|September 28, 2018
[Eosinophilia]Ole Weis Bjerrum, Daniel El Fassi, Gitte Madsen, et al.
Blood|January 27, 2017
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CMLRebecca Warfvinge, Linda Geironson, Mikael N E Sommarin, et al.
Journal of Cancer Research and Clinical Oncology|March 25, 2017
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemiaHanna L M Rajala, Mohamed El Missiry, Anniina Ruusila, et al.
Oncoimmunology|August 21, 2019
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-lineAnna Kreutzman, Bhagwan Yadav, Tim H Brummendorf, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Ugeskrift for Laeger|January 26, 2011
[The pathogenesis of primary immune thrombocytopenia]Sif Gudbrandsdottir, Henrik Frederiksen, Henrik Sverre Birgens, et al.
Ugeskrift for Laeger|January 26, 2011
[New treatment options for primary immune thrombocytopenia]Sif Gudbrandsdottir, Henrik Frederiksen, Henrik Sverre Birgens, et al.
The Lancet. Haematology|December 22, 2015
Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort studyHenrik Frederiksen, Dóra Körmendiné Farkas, Christian Fynbo Christiansen, et al.
Ugeskrift for Laeger|January 29, 2009
[Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences]Peter Hokland, Hans Beier Ommen, Charlotte Guldborg Nyvold, et al.
Ugeskrift for Laeger|January 29, 2009
[Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation]Peter Hokland, Charlotte Guldborg Nyvold, Jesper Stentoft, et al.
Ejhaem|August 22, 2025
Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria: Real World Data From Denmark and FinlandAnders Rønneholt-Frederiksen, Dennis Lund Hansen, Vuokko Nummi, et al.
Ugeskrift for Laeger|September 28, 2018
[Eosinophilia]Ole Weis Bjerrum, Daniel El Fassi, Gitte Madsen, et al.
Blood|January 27, 2017
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CMLRebecca Warfvinge, Linda Geironson, Mikael N E Sommarin, et al.
Journal of Cancer Research and Clinical Oncology|March 25, 2017
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemiaHanna L M Rajala, Mohamed El Missiry, Anniina Ruusila, et al.
Oncoimmunology|August 21, 2019
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-lineAnna Kreutzman, Bhagwan Yadav, Tim H Brummendorf, et al.
Pageof 4